Cargando…

Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer

Fibroblast growth factor receptor 2 (FGFR2) is a membrane-spanning tyrosine kinase that mediates signaling for FGFs. Recent studies detected various point mutations of FGFR2 in multiple types of cancers, including breast cancer, lung cancer, gastric cancer, uterine cancer and ovarian cancer, yet the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Haipeng, Deng, Chu-Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666331/
https://www.ncbi.nlm.nih.gov/pubmed/29104507
http://dx.doi.org/10.7150/ijbs.20792
_version_ 1783275288529993728
author Lei, Haipeng
Deng, Chu-Xia
author_facet Lei, Haipeng
Deng, Chu-Xia
author_sort Lei, Haipeng
collection PubMed
description Fibroblast growth factor receptor 2 (FGFR2) is a membrane-spanning tyrosine kinase that mediates signaling for FGFs. Recent studies detected various point mutations of FGFR2 in multiple types of cancers, including breast cancer, lung cancer, gastric cancer, uterine cancer and ovarian cancer, yet the casual relationship between these mutations and tumorigenesis is unclear. Here we will discuss possible interactions between FGFR2 signaling and several major pathways through which the aberrantly activated FGFR2 signaling may result in breast cancer development. We will also discuss some recent developments in the discovery and application of therapies and strategies for breast cancers by inhibiting FGFR2 activities.
format Online
Article
Text
id pubmed-5666331
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-56663312017-11-04 Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer Lei, Haipeng Deng, Chu-Xia Int J Biol Sci Review Fibroblast growth factor receptor 2 (FGFR2) is a membrane-spanning tyrosine kinase that mediates signaling for FGFs. Recent studies detected various point mutations of FGFR2 in multiple types of cancers, including breast cancer, lung cancer, gastric cancer, uterine cancer and ovarian cancer, yet the casual relationship between these mutations and tumorigenesis is unclear. Here we will discuss possible interactions between FGFR2 signaling and several major pathways through which the aberrantly activated FGFR2 signaling may result in breast cancer development. We will also discuss some recent developments in the discovery and application of therapies and strategies for breast cancers by inhibiting FGFR2 activities. Ivyspring International Publisher 2017-09-05 /pmc/articles/PMC5666331/ /pubmed/29104507 http://dx.doi.org/10.7150/ijbs.20792 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Lei, Haipeng
Deng, Chu-Xia
Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer
title Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer
title_full Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer
title_fullStr Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer
title_full_unstemmed Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer
title_short Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer
title_sort fibroblast growth factor receptor 2 signaling in breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666331/
https://www.ncbi.nlm.nih.gov/pubmed/29104507
http://dx.doi.org/10.7150/ijbs.20792
work_keys_str_mv AT leihaipeng fibroblastgrowthfactorreceptor2signalinginbreastcancer
AT dengchuxia fibroblastgrowthfactorreceptor2signalinginbreastcancer